Avalyn Pharma Inc. (AVLN)
| Market Cap | 1.23B |
| Revenue (ttm) | n/a |
| Net Income | -85.20M |
| EPS | -4.56 |
| Shares Out | 41.81M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 6,312,729 |
| Open | 26.00 |
| IPO Price | 18.00 |
| Day's Range | 26.00 - 30.20 |
| 52-Week Range | 18.00 - 30.16 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | n/a |
About AVLN
Avalyn Pharma Inc. operates as a clinical-stage biopharmaceutical company developing inhaled medicines to treat rare respiratory diseases, including pulmonary fibrosis and other interstitial lung diseases. The company provides inhaled formulations of oral medicines directly to the lungs. Its current pipeline is focused on treating pulmonary fibrosis. Its products include AP01 and AP02, inhaled formulations of pirfenidone and nintedanib for the treatment of progressive pulmonary fibrosis and idiopathic pulmonary fibrosis; and AP03, a fixed-dose ... [Read more]
News
Avalyn Announces Pricing of Upsized Initial Public Offering
BOSTON, April 29, 2026 (GLOBE NEWSWIRE) -- Avalyn Pharma Inc. (Nasdaq: AVLN) (“Avalyn”), a clinical-stage biopharmaceutical company pioneering inhaled therapies to transform the treatment paradigm of ...
Avalyn Pharma IPO Registration Document (S-1)
Avalyn Pharma has filed to go public with an IPO on the NASDAQ
Pulmonary fibrosis biotech Avalyn Pharma files for a $100 million IPO
Avalyn Pharma, a Phase 2 biotech developing inhaled medicines for rare respiratory diseases, filed on Wednesday with the SEC for an initial public offering. The company used a placeholder of $100 mill...